Advances in delivery technologies, including nanoparticles, lipid nanoparticles, and hydrogels, are improving peptide stability and enabling targeted presentation to the immune system
Aqu se suministra como material de investigacin (RUO), no para consumo humano
The results show that women tend to use GLP-1 drugs at higher rates than men, although there is considerable variability within age groups
What clinicians consider when advising against GLP-1 use during breastfeeding Lack of large, controlled lactation safety trials Unknown effects on infant growth or neurodevelopment Uncertainty about effects on milk supply or composition Elective nature of GLP-1 therapy for weight loss Availability of safer alternatives after breastfeeding ends Why FDA and medical guidance remains cautious FDA and specialty guidance emphasize caution during breastfeeding for several consistent reasons: Insufficient data: FDA labeling states there are inadequate data on GLP-1 medication effects in breastfed infants.,, Milk supply unknowns: It is not known whether GLP-1 medications affect milk supply (volume) or milk composition., Infant vulnerability: Early infancy is a sensitive developmental period, increasing caution when medication effects are unknown. Elective vs essential use: For weight management, potential maternal benefit often does not outweigh theoretical infant risk.,, Do semaglutide and tirzepatide pass into breast milk
Key Products: The company develops vaccines (including COVID-19 and Prevnar), cancer treatments, and has programs for rare diseases and gene therapy candidates
